


**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

<b>VALUE DRUG COMPANY</b>	<b>:</b>	<b>CIVIL ACTION</b>
	<b>:</b>	
<b>v.</b>	<b>:</b>	<b>NO. 21-3500</b>
	<b>:</b>	
<b>TAKEDA PHARMACEUTICALS,</b>	<b>:</b>	
<b>U.S.A., INC., PAR</b>	<b>:</b>	
<b>PHARMACEUTICAL, INC., WATSON</b>	<b>:</b>	
<b>LABORATORIES, INC., TEVA</b>	<b>:</b>	
<b>PHARMACEUTICAL INDUSTRIES,</b>	<b>:</b>	
<b>LTD., TEVA PHARMACEUTICALS</b>	<b>:</b>	
<b>USA, INC., AMNEAL</b>	<b>:</b>	
<b>PHARMACEUTICALS, LLC</b>	<b>:</b>	

**ORDER**

**AND NOW**, this 23<sup>rd</sup> day of November 2022, upon considering Plaintiff's Motion to certify a class (ECF Doc. No. 483), Defendants' Response (ECF Doc. No. 527), Plaintiff's Reply (ECF Doc. No. 543), the parties' pre-hearing Memoranda (ECF Doc. Nos. 592, 593), following our extensive November 1, 2022 evidentiary hearing and oral argument, and for reasons in the accompanying Memorandum, it is **ORDERED** Plaintiff's Motion to certify a class (ECF Doc. No. 483) is **DENIED** without prejudice.



KEARNEY, J.